There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Galapagos NV (NASDAQ:GLPG) and Exact Sciences (NASDAQ:EXAS) with bullish sentiments.
Galapagos NV (GLPG)
Stifel Nicolaus analyst Adam Walsh maintained a Buy rating on Galapagos NV today and set a price target of $111. The company’s shares closed yesterday at $102.74.
According to TipRanks.com, Walsh is a 4-star analyst with an average return of 17.5% and a 50.0% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics Inc, Galmed Pharmaceuticals, and Reata Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Galapagos NV with a $111.20 average price target.
See today’s analyst top recommended stocks >>
Exact Sciences (EXAS)
In a report released today, Mark Massaro from Canaccord Genuity maintained a Buy rating on Exact Sciences, with a price target of $87. The company’s shares closed yesterday at $75.91, close to its 52-week high of $80.35.
According to TipRanks.com, Massaro is a top 100 analyst with an average return of 19.9% and a 64.0% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Idexx Laboratories, and Genomic Health.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Exact Sciences with a $84.57 average price target, an 11.4% upside from current levels. In a report issued on September 5, Cowen & Co. also reiterated a Buy rating on the stock with a $100 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on EXAS:
